deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04010357

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Targeted Therapy With CDK4/6 Inhibitors in Chemo- Refractory/Relapsed, Rb Wild-type Extensive Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Lung Cancer, Extrapulmonary Small Cell Cancers and Other High Grade Neuroendocrine Cancers of the Lung, an Open Label Phase 2 Trial.

Sponsor: Case Comprehensive Cancer Center

Conditions Extrapulmonary Small Cell Carcinoma Large Cell Neuroendocrine Carcinoma of the Lung Small-cell Lung Cancer
Interventions Abemaciclib,
Updated 17 times since 2019 Last updated: Dec 1, 2025 Started: Jan 13, 2020 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04010357, this PHASE2 trial focuses on Extrapulmonary Small Cell Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung and remains ongoing. Sponsored by Case Comprehensive Cancer Center, it has been updated 17 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Dec 2020 · 10 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Nov 2023 · 8 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Jul 2025 · 3 months · monthly snapshot~Jul 2025 – ~Jan 2026 · 6 months · monthly snapshot~Jan 2026 – present · 8 months · monthly snapshot

Change History

17 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jul 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  3. Apr 2025 — Jul 2025 [monthly]

    Recruiting PHASE2

  4. Sep 2024 — Apr 2025 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 12 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Nov 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

  3. Mar 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  4. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  5. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  6. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  7. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  9. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Feb 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Nov 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

  12. Aug 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Case Comprehensive Cancer Center
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations